Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Cold Medicine Could Stop Cancer Spread

By Hokkaido University | October 18, 2016

Tumor growth in the xenograft bladder cancer model was monitored using a bioluminescence imaging system. Forty-five days after inoculation, metastatic tumors were detected in the lungs, liver and bone. (Credit: Matsumoto R. et. al., Scientific Reports, Oct. 4, 2016)

Bladder cancer is the seventh most common cancer in males worldwide. Every year, about 20,000 people in Japan are diagnosed with bladder cancer, of whom around 8,000 — mostly men — succumb to the disease. Bladder cancers can be grouped into two types: non-muscle-invasive cancers, which have a five-year survival rate of 90 percent, and muscle-invasive cancers, which have poor prognoses. The latter are normally treated with such anticancer drugs as cisplatin, but tend to become chemoresistant and, thus, spread to organs such as the lungs and liver, as well as bone.

In the latest research, human bladder cancer cells labeled with luciferase were inoculated into mice, creating a xenograft bladder cancer model. The primary bladder xenograft gradually grew and, after 45 days, metastatic tumors were detected in the lungs, liver and bone. By using a microarray analysis including more than 20,000 genes for the metastatic tumors, the team discovered a three- to 25-fold increase of the metabolic enzyme aldo-keto reductase 1C1 (AKR1C1). They also found high levels of AKR1C1 in metastatic tumors removed from 25 cancer patients, proving that the phenomena discovered in the mice also occur in the human body. Along with anticancer drugs, an inflammatory substance produced around the tumor, such as interleukin-1β, increased the enzyme levels.

The researchers also identified for the first time that AKR1C1 enhances tumor-promoting activities and proved that the enzyme blocks the effectiveness of cisplatin and other anticancer drugs.

The researchers finally discovered that inoculating flufenamic acid, an inhibitory factor for AKR1C1, into cancerous bladder cells suppressed the cells’ invasive activities and restored the effectiveness of anticancer drugs. Flufenamic acid is also known as a nonsteroid anti-inflammatory drug used for treating common colds.

The team’s discovery is expected to spur clinical tests aimed at improving prognoses for bladder cancer patients. In the latest cancer treatments, expensive molecular-targeted drugs are used, putting a large strain on both the medical economy and the state coffers. “This latest research could pave the way for medical institutions to use flufenamic acid — a much cheaper cold drug — which has unexpectedly been proven to be effective at fighting cancers,” says Dr. Shinya Tanaka of the research group.

The research was conducted in collaboration with Dr. Nobuo Shinohara of the Department of Renal and Genitourinary Surgery at Hokkaido University; the article’s lead author was postgraduate student Ryuji Matsumoto.


Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE